Samuel Miller Laboratory, Seattle, WA

 
The Miller laboratory is focused on defining the molecular basis of bacterial pathogenesis and interactions with eukaryotic cells.

The lab is organized into research groups focusing on the study of:

Salmonellae translocated effectors (which are delivered across the phagosome membrane and recruited to the actin cytoskeleton, nucleus, and phagosome).

  • Funding: 5R01AI048683-12 Title: SALMONELLA PATHOGENICITY ISLAND 2 EFFECTOR PROTEINS.

Bioinformatic analysis, DNA sequencing and phenotypic comparison of Shigella and Salmonella outbreak strains from diverse geographic locations including Central America and Africa.

  • Funding: 5U19AI090882-03 Sub-Project ID: 7513 Title: GENOTYPIC CORRELATES OF PATHOGEN DIVERSITIY OF NTS IN AFRICA AND NORTH AMERICA.

Molecular basis of NONTYPHOIDAL Salmonella emergence.

  • Funding: 5U19AI090882-03 Title: ERIN CRC: MOLECULAR BASIS OF NONTYPHOIDAL SALMONELLA EMERGENC.

The environmental remodeling of the gram-negative bacterial envelop that occurs when bacteria infect host tissues.

  • Funding:# 5R01AI030479-23  Title:PHOP REGULON AND SALMONELLA VIRULENCE.

Using NMR and crystallography to define structural mechanisms by which PhoQ responds to antimicrobial peptides and low pH.

  • Funding:# 5R01AI030479-23  Title:PHOP REGULON AND SALMONELLA VIRULENCE.

Identification of human genome polymorphisms that alter susceptibility to bacterial infection and diversity of human immune responses.

  • Funding: 5U54AI057141-09 Sub-Project ID: 6254.Title: DIVERSITY OF HOST PATHOGEN INTERACTIONS.

How bacterial second messenger di-c-GMP affects organellar function, and development of new antimicrobial compounds to inhibit second messenger signaling.

  • Funding: 5U54AI057141-09. Title: NW RESEARCH CENTER FOR EXCELLENCE IN BIODEFENSE AND EMERGING INFECTIOUS DISEASES; sub project: 5U54AI057141-09 #6221 Title: ANTIBIOTIC DRUG DISCOVERY.

Human microbiota in inflammatory bowl disease.

About Dr. Samuel I Miller.

Samuel I. Miller is a Professor of Medicine, Microbiology, Immunology and Genome Sciences at the University of Washington.  He has been the Director of the NIAID Northwest Research Center for Excellence in Biodefense and Emerging Infectious Diseases since its inception in 2003 and of the University of Washington Enteric Research Investigative Center of NIAID since 2010.  He is the past Director of the Cystic Fibrosis Research and Development Program at the U W.  He received his B.A. from John Hopkins University in 1975 and M.D. in 1979 from Baylor College of Medicine and was an Intern, Resident, Fellow, Assistant and Associate Professor at the Massachusetts General Hospital and Harvard Medical School.   His research training was in the laboratories of Dr. Dyann Wirth (Harvard School of Public Health, molecular parasitiology) and Dr. John Mekalanos (Harvard Medical School, bacterial pathogenesis).

Dr. Miller has received a number of honors, including the Squibb Award from the Infectious Diseases Society of America and has been elected to the American Academy of Microbiology, the American Society of Clinical Investigation, and the American Association of Physicians.  His laboratory is focused on defining the molecular basis of bacterial pathogenesis and interactions with eukaryotic cells, with a special emphasis on innate immune response to Gram-negative bacteria. Some of Dr. Miller’s important contributions include: defining how Salmonella senses antimicrobial peptides and pH to promote pathogenesis, environmental regulation of Lipid A structure of Gram-negative bacteria to promote resistance to antimicrobial peptides and alter recognition by mammalian LPS receptor complex, definition of structure and function of type III secretion machinery and effector proteins, the definition of important genetic and functional adaptations of Pseudomonas aeruginosa infecting the airways of individuals with cystic fibrosis,  and recently, the development of technology to define human diversity in innate immune recognition of bacteria, and a development of a biosensor for c-di-GMP to visualize second messenger dynamics in living bacteria.

Office Phone: (206) 616-5110
Fax: (206) 616-4295
Office Location: Health Sciences K-140, Box 357710
Email: millersi [ a  t ] uw.edu